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Abstract: Meningococcal conjugate vaccines have several advantages over polysaccharide 
  vaccines, including the ability to induce greater antibody persistence, avidity, immunologic 
memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs have been 
established across the globe. Many of these vaccination programs have resulted in significant 
decline in meningococcal disease in several countries. Recent introduction of serogroup A 
  conjugate vaccine in Africa offers the potential to eliminate meningococcal disease as a public 
health problem in Africa. However, the duration of immune response and the development of 
widespread herd immunity in the population remain important questions for meningococcal 
  vaccine programs. Because of the unique epidemiology of meningococcal disease around 
the world, the optimal vaccination strategy for long-term disease prevention will vary by 
country.
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Introduction
Though the incidence is relatively low, many industrialized countries prioritize 
meningococcal disease prevention due to its rapid onset, fulminant nature, high 
case fatality ratio, and long-term sequelae. The advent of conjugate vaccines against 
  common meningococcal serogroups has proven a major advancement in   controlling 
meningococcal disease. The UK was the first country to launch a national meningococcal 
conjugate vaccination program in 1999 using a serogroup C vaccine, resulting in a 
dramatic decline in serogroup C disease.1 In contrast to industrialized countries, the 
burden of meningococcal disease in the sub-Saharan African “meningitis belt” is large 
and frequent epidemics occur that are disruptive to the public health infrastructure.2 
The development of a safe, effective, affordable conjugate vaccine against serogroup A 
meningococcal disease is a tremendous advance that has the potential to eliminate 
epidemic meningococcal disease as a public health concern in Africa.
Meningococcal conjugate vaccines were developed to overcome the limitations 
of polysaccharide vaccines. The defining characteristic of the protein–polysaccharide 
conjugate vaccine is the ability to induce a T-cell dependent immune response. The 
resulting immunologic benefits include priming for a memory response, antibody 
avidity maturation, development of protective antibodies in young children, and 
  reduction of nasopharyngeal carriage. Conjugate meningococcal vaccines have the 
potential to protect unvaccinated age groups in a population through herd immunity. 
This review will focus on meningococcal conjugate vaccines and the impact of 
  vaccination programs on meningococcal epidemiology.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Meningococcal disease
Meningococcal disease most commonly presents as a blood-
stream infection or meningitis, with other localized infections 
such as pneumonia presenting less commonly. Bloodstream 
infection can occur with or without other localized infec-
tion. Meningococcemia, or fulminant bloodstream infection, 
occurs in approximately 20% of patients with bacteremia and 
results from rapid proliferation of meningococci in the blood. 
The overall case fatality ratio for meningococcal disease is 
approximately 10%–15%, and is as high as 25%–30% in 
patients with meningococcemia. Disease onset is often rapid, 
and death may occur within 24 hours in the absence of anti-
microbial therapy. Globally, there are approximately 614,000 
cases annually with the highest incidence in sub-Saharan 
Africa (10–25 per 100,000). The incidence in Canada, the 
US, and Europe varies substantially by country, ranging 
from 0.35 per 100,000 to three per 100,000 persons per year.3 
Incidence also varies by age with infants at greatest risk and 
a second peak in incidence observed among adolescents in 
most industrialized countries.
Neisseria meningitidis is a Gram-negative, encapsulated 
diplococcus that exclusively infects humans. Thirteen   distinct 
serogroups have been identified based on their capsular 
polysaccharide, with serogroups A, B, C, Y, and W-135 
accounting for nearly all disease. Serogroup distribution 
varies globally, with serogroup A predominant in Africa, 
and serogroups B, C, and Y observed in Asia, Europe, 
and the Americas with variable frequency.4 Age-specific 
incidence also varies. In the US, serogroup B accounts for 
approximately 65% of infant disease, while serogroups C 
and Y cause the majority of disease in adolescents and sero-
group Y predominates in the elderly.5
Neisseria meningitidis is a transient commensal of 
the human nasopharynx. Acquisition of the organism 
and colonization of the nasopharynx is necessary for the 
development of disease, but not sufficient. In the majority of 
cases, carriage is an immunizing event, resulting in protective 
antibodies that prevent disease. The prevalence of carriage is 
highly variable. In industrialized countries, meningococcal 
carriage is observed in roughly 10% of the population 
overall, rising from 2% in children under 4 years to a peak of 
24.5%–32% among 15- to 24-year-olds, then declining with 
increasing age.6,7 Though carriage prevalence can mirror the 
overall epidemiology of disease, the relationship between 
risk factors for disease and those associated with carriage 
is incompletely understood. Further, carriage prevalence 
does not predict the incidence of disease nor the occurrence 
or severity of outbreaks. Even in settings of outbreaks or in 
hyperendemic disease, nasopharyngeal carriage of disease-
associated strains may be exceedingly rare. Serogroup and 
molecular diversity is greater among carried isolates than 
among invasive isolates.8
Correlates of protection against 
meningococcal disease
Because of the low incidence of meningococcal disease, 
  prelicensure vaccine efficacy trials employing disease 
outcomes are not feasible. Meningococcal vaccines 
are evaluated and licensed based on evidence of an immune 
response in subjects receiving vaccine using serum 
bactericidal activity (SBA) as the immunologic correlate 
of protection. Goldschneider et al demonstrated that serum 
bactericidal antibody levels correlate with protection against 
meningococcal disease using human complement (hSBA). 
Titers of four to eight were shown to confer protection 
against disease and hSBA has since been considered the gold 
standard correlate of protection.9,10 In addition, SBA titers 
of $128 using baby rabbit complement (rSBA) have been 
shown to predict protection in humans.11–13 Postlicensure 
studies in the UK validated these correlates of protection, 
and additionally proposed that titers between eight and 64 
are also likely to be protective.14 While these correlates of 
protection have been evaluated for serogroup C disease, they 
have been generally used as correlates of protection for other 
serogroups. Controversy remains over the “best” complement 
source, and regulatory agencies have different requirements 
for testing in prelicensure trials.
Polysaccharide vaccines
Meningococcal polysaccharide vaccines have been in 
use since the 1970s. There are several combinations used 
  globally, including bivalent (A,C), trivalent (A,C,W-135), 
and quadrivalent (A,C,Y, W-135) vaccines. The effectiveness 
of capsular polysaccharide vaccines has been demonstrated 
in military recruits, community outbreaks, and house-
hold contacts of affected individuals.15–18 Serogroup A 
  vaccines have also been used effectively during outbreaks 
in Africa.19–21
The immunologic characteristics of capsular polysac-
charide vaccines limit their impact in preventive vac-
cination programs. The polysaccharide antigen is T-cell 
independent and stimulates antibody production in mature 
B-lymphocytes. Without a T-cell mediated response, there 
is no class switching, affinity maturation, or development 
of memory cells.22,23 Polysaccharide vaccines are not as effec-
tive in infants because infants lack the mature lymphocytes Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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required for a robust immune response. Infants vaccinated 
between 7 and 12 months of age have an SBA concentra-
tion indistinguishable from unimmunized children by 
24 months of age24 and effectiveness rapidly declines to 8% 
in children under 4 years of age.25 Moreover, revaccination 
does not induce a booster response and multiple doses may 
result in hypo-responsiveness to subsequent doses, although 
the   clinical significance of this is unclear.26–28 Finally, 
polysaccharide vaccines do not completely protect from 
acquisition of nasopharyngeal carriage and therefore they 
do not provide long-term herd immunity.29,30
Conjugate vaccines
Conjugation of capsular polysaccharides to a protein carrier 
results in a T-dependent immune response. These carrier 
proteins are presented by polysaccharide specific B-cells 
to helper T-cells, enhancing production of plasma cells and 
memory B-cells. The result is a more robust immune response 
compared with polysaccharide vaccines, including greater 
antibody persistence, greater avidity, and long-term immuno-
logic memory.31 Conjugate vaccines to respiratory bacterial 
pathogens are immunogenic in infants, and protect against 
acquisition of nasopharyngeal carriage. Several   formulations 
of meningococcal conjugate vaccines are   currently available 
(Table 1). Their composition varies greatly and differences in 
capsular serogroup used, modification of the capsular antigen, 
type of carrier protein used, and the method of conjugation 
all can affect the characteristics of the immune response and 
therefore the effectiveness of the vaccine. Vaccine effective-
ness is also dependent on the targeted   vaccination group 
and the dosing schedule. Immune responses and waning 
immunity are age dependent, with young infants and chil-
dren requiring more doses and demonstrating more rapid 
decline in antibody levels compared to older children and 
adolescents.31
The contribution of the memory response to duration of 
protection of meningococcal vaccines is unclear.   Studies sug-
gest that circulating antibody is needed for protection from 
meningococcal vaccines due to the rapid onset of disease; 
therefore antibody persistence studies can be used to estimate 
duration of protection of meningococcal vaccines.32 Because 
vaccine licensure studies rely on short-term immunoge-
nicity as the evaluated outcome, disease surveillance and 
postlicensure evaluations of meningococcal vaccination 
programs are critical for determining the most effective 
  vaccination strategies.
Immunogenicity of monovalent 
serogroup C vaccines
Meningococcal serogroup C (MCC) vaccines were introduced 
in the UK in 1999 in response to high rates of serogroup C 
disease caused by a virulent clone (Table 1).1 The safety 
and immunogenicity of the three different MCC vaccines 
in children and adults have been demonstrated in several 
studies, and there are no substantial differences in effective-
ness between the vaccine types.33–40 Ninety-eight percent 
of infants develop rSBA titers $8, the putative   correlate of 
protection, following a three-dose series at 2, 3, and 4 months 
of age.33,36–38,41 Similar immune responses are seen following 
a two-dose series at 3 and 5 months as well as a single dose 
in older children and adults.42–44,47
Antibody persistence has been followed closely after 
MCC vaccination in the UK, and waning immunity is dem-
onstrated, especially in infants and young children. In the 
absence of a booster dose, only 8%–12% of children complet-
ing a three-dose series in infancy had rSBA titers $8 at age 
4 years.45 Among 250 children primed at ages ranging from 
2 months to 6 years, only 25% (95% confidence interval [CI]: 
20%–30%) had protective rSBA titers $8 at 1 year.46 Among 
children who received a single dose of MCC vaccine at age 
2 years, 37% had a titer $8, 2 years later.48 Even following 
a booster dose in the second year of life only 23%–43% of 
children maintained protective SBA titers 2 years later.49 
Waning immunity among adolescents vaccinated with 
MCC is much less pronounced. In two studies of adoles-
cents vaccinated at age 10 years, 62%–75% of adolescents 
vaccinated maintained protective hSBA titers $8 3–6 years 
following vaccination.47,50 In a third study, Snape et al found 
Table 1 Meningococcal conjugate vaccine products1
Vaccine Manufacturer Serogroups Protein conjugate
Menveo™ Novartis vaccines A, C, Y, w-135 Diphtheria cross-reactive material 197 (CRM197)
Menactra™ Sanofi Pasteur A, C, Y, w-135 Diphtheria toxoid
Meningitec™ wyeth vaccines C CRM197
Menjugate® Novartis vaccines C CRM197
Neisvac-C™ Baxter Bioscience C Tetanus toxoid
MenAfrivac™ Serum Institute of India A Tetanus toxoid
1Adapted with permission from vaccines, 5th ed, Granoff et al, Meningococcal vaccines, p 399–434, Copyright elsevier (2008).93Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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that 5-year postvaccination GMT titers were significantly 
greater in children vaccinated after age 10 years than those 
vaccinated at age 6–10 years.51 These studies suggest that 
immune maturation may play an important role in duration 
of protection.
Immunogenicity of quadrivalent 
serogroup A, C, Y,   W-135 vaccines
Two quadrivalent (A, C, Y, W-135) meningococcal conjugate 
vaccines are licensed in the US (Table 1). While these 
  vaccines are often recommended and used for protection 
against serogroup A in travelers, the US is the only country 
that employs a routine program of immunization due to 
the proportion of meningococcal disease caused by sero-
group Y.
Prelicensure trials for MenACWYD demonstrated the 
safety and immunologic noninferiority to quadrivalent 
  polysaccharide vaccine. At 28 days after a single dose, 
a   similar high proportion of 11- to 18-year-old subjects 
achieved at least a four-fold rise in rSBA titers, and the 
proportion achieving rSBA of $128 was .98% for all sero-
groups for both   vaccines.52 Comparable results were dem-
onstrated for adults ages 18 through 55 years, with .97% 
rSBA $128 for all serogroups for both vaccines.53 High rates 
of protective rSBA titers $128 were also demonstrated in 
children aged 2–10 years with levels varying depending 
on the serogroup (81% for   serogroup C to 97% for sero-
group A).54
MenACWYCRM is a second quadrivalent vaccine using 
diphtheria cross-reactive protein as the carrier protein. A 
randomized controlled trial conducted among persons aged 
11–18 years demonstrated   noninferiority of   MenACWYCRM 
compared to MenACWYD for all four serogroups. The 
  proportions of subjects with rSBA seroresponse were 
statistically higher for serogroups A, W-135, and Y in the 
MenACWYCRM group,   compared with the MenACWYD 
group.55 Other   randomized controlled trials among persons 
aged 19–55 years and   children aged 2–10 years demonstrated 
similar results.56,57 While   statistically significant, these 
  differences were small and assays have not been standard-
ized, making direct comparisons   somewhat difficult. The 
clinical relevance of the higher   postvaccination immune 
responses is not known.
The duration of protection following vaccination 
with quadrivalent meningococcal conjugate vaccines 
remains an important subject of evaluation. Persistence 
of protective levels of antibodies 3 years postvaccination 
as well as immunologic priming have been demonstrated 
in adolescent recipients of MenACWYD; however, studies 
are inconsistent and all demonstrate significant declines 
in antibody levels over 3 years.52,58 For serogroup C, geo-
metric mean titers (GMT) declines as much as 90% over 
3 years and the proportion of adolescents with   protective 
antibodies is as low as 30%–54%.52,59 The proportion of 
2-year-olds with hSBA titers $4 6 months   following vac-
cination was approximately 50% for serogroups C, Y, and 
W-135.60,61 Similar decline in the duration of protection 
is seen with MenACWYCRM. At 22 months postvaccina-
tion, 34% (serogroup A) to 84% (Serogroup W-135) had 
hSBA $8.59 Concerns of waning immunity prompted the 
US to recommend a booster dose as part of its adolescent 
immunization program.62
Immunogenicity of monovalent 
serogroup A conjugate vaccine
Epidemic meningococcal disease remains a devastating 
public health problem in the sub-Saharan African 
meningitis belt, stretching across the Sahel from Senegal 
to Ethiopia. Annual incidence averages from 25–100 
cases per 100,000 persons, and can exceed 1000 cases per 
100,000 during peak epidemic years. Serogroup A is the 
predominant disease- and outbreak-associated serogroup in 
the region.3 Polysaccharide vaccines have been used with 
some success for many years to limit the extent of disease 
in outbreak settings. Until recently, fiscal and logistical 
considerations prevented the development and large-scale 
introduction of a conjugate vaccine as part of a preventive 
vaccination program. In 2010, MenAfriVac, a new 
meningococcal A – tetanus toxoid conjugate vaccine was 
licensed for persons aged 1–29 years old and prequalified 
by the World Health Organization for use in Africa. 
Since September 2010, over 20 million people have been 
vaccinated in Burkina Faso, Mali, and Niger. This is the 
first large-scale introduction of a meningococcal conjugate 
vaccine in Africa. At a price of US$0.40 per dose, the 
current strategy of mass vaccination of all 1–29 year olds 
is within reach of even the poorest countries of the region. 
Subsequent vaccination of infants, if necessary, will 
require further mobilization of support from additional 
donors.63
In a published prelicensure trial of 105 adults aged 
18–35 years who received one dose of MenA vaccine, 
100% and 92% of subjects had protective titers by 4 weeks 
postvaccination by rSBA and hSBA, respectively. Greater 
than four-fold increases in antibody titers were seen in 
83% and 87% of subjects, with demonstrated antibody Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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persistence at 1 year. Using rSBA assays, 100% of subjects 
with a four-fold rise in titers maintained this response at 
1 year postvaccination. Protective rSBA titers $8 as well 
as   MenA IgG . 2 mg/mL 1 year postvaccination were also 
seen in 100% of patients.64,65 Data from these trials are similar 
to that seen in other meningococcal conjugate vaccines. 
Continued effectiveness studies in the field are ongoing and 
necessary to evaluate the long-term effect of this vaccine on 
epidemic meningococcal disease.
Immunologic memory and booster 
response after meningococcal 
conjugate vaccination
Conjugate vaccines elicit immunologic memory, but memory 
may not play as important a role in protection against 
meningococcal disease compared to Haemophilus influenza 
and Strepcococcus pneumoniae. Meningococcal conjugate 
vaccines prime the immune system and immunologic 
memory persists even in the absence of detectable   bactericidal 
antibodies. In a study of 4-year-olds in whom postconjugate 
vaccination titers had declined to prevaccination levels, 
boosting with meningococcal polysaccharide vaccine 
resulted in a 1000-fold increase in geometric mean titers and 
geometric mean avidity index was 1.33-fold higher 1 month 
following the vaccine. High GMTs are achieved after boost-
ing following a single primary dose of MCC at 12 months 
of age.37,38,43,46,66–70
A strong association has been noted between MCC- 
specific antibody levels and the number of memory B cells 
measured after immunization. This level correlates with 
antibody persistence at 1 year, suggesting the impor-
tance of persistence of functional antibody in long-term 
humoral immunity.71 However, additional studies of the 
kinetics of antibody responses following boosting show that 
it takes up to 10 days to achieve protective SBA titers $8 in 
adults.72 If antibody presence wanes, this lag may not be rapid 
enough to protect against infection with N. meningitidis, 
considering the rapid onset of disease. Analyses of break-
through cases following vaccination have found evidence 
of priming but low SBA activity. An anamnestic immune 
response is observed, but is hypothesized not to occur prior 
to development of invasive disease.32
Meningococcal vaccine programs 
and vaccine effectiveness
Since routine meningococcal vaccination was introduced in 
the UK in 1999, vaccination programs have expanded across 
Europe, Australia, and North America (Table 2).73–79 These 
programs have been implemented using various schedules and 
target age groups.1,77,78,80,81 In general, vaccine effectiveness 
estimates have paralleled immunogenicity data, but the 
observed public health impact of these programs is likely 
a combination of the vaccines used, the target age groups, 
and the recommended schedule. While some countries have 
implemented routine recommendations for a specific age 
group, others have implemented catch-up campaigns in 
addition to routine recommendations, more rapidly achieving 
high vaccine coverage and population protection. Differences 
in circulating strain diversity may also contribute to vary-
ing vaccine effectiveness, and postlicensure studies have 
Table 2 Global meningococcal conjugate vaccine programs
Country Vaccine product Year  
introduced
Schedule
UK94 Men C Conjugate (MenC) 1999 Routine primary series at 3 and 4 mo with booster at 12 mo1
Canada95 Men C 
Men ACYwd
2 (PeI and NB only)4
2002 
2006
Single dose at 12 mo (most provinces) with catch up  
through age 20 yrs
Australia Men C 2003 Single dose at 12 mo
USA Men ACwYd
2 2005 Single dose at age 11–18 years; booster dose in 5 years;  
from age 2 years in certain high risk groups Men ACwYcrm
3 2010
Spain85 Men C 2000 Routine primary series at 2, 4, and 6 mo with catch up  
through age 6 yrs (3 provinces through adolescence)
Ireland96 Men C 2000 Routine primary series at 4 and 6 mo with booster at 12 mo
Netherlands79 Men C 2002 1 dose at 14 mo
Belgium97 Men C 2002 1 dose at 12 mo
Germany97 Men C 2006 1 dose 12–23 mo
Greece75 Men C 2001 Single dose at 12 mo5
Africa (Burkina, Mali, Niger) Men A 2010 Mass vaccination of 1- to 29-year-olds with single dose
Notes: 12, 4, 6 months 1999–2006; 2Men A, C, Y, w-135 conjugated to diphtheria toxoid; 3Men A, C, Y, w-135 conjugated to diphtheria cross-reactive material 197; 4Prince 
edward Island; New Brunswick; 5voluntary participation by providers; may be given up to 14 years.
Abbreviation: mo, months.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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demonstrated the importance of reduction in carriage and 
herd immunity.84–88
In the UK, vaccine effectiveness in adolescents (93%) was 
sustained up to 4 years after the catch-up vaccination. While 
effectiveness was high (83%) in those receiving catch-up 
immunization after 5 months of age, it was lower among 
those vaccinated in infancy (66%).82,83 In Spain, vaccine 
effectiveness greater than 1 year postvaccination was 78% 
among those vaccinated in infancy, but 94% among chil-
dren ages 7 months–5 years at vaccination.84,85 VE studies 
in United States are ongoing, but initial estimates suggest 
vaccine effectiveness wanes to 50%–60% 2–5 years after 
vaccination.87
Conjugate vaccine programs have potential to provide 
indirect protection through herd immunity. Two years after 
introduction of MCC vaccine in the UK, serogroup C carriage 
was reduced by 67%.86 Attack rates among unvaccinated 
children in the UK also declined by 67% in the 4 years 
following vaccine introduction. Between 1998 and 2009, 
the incidence of serogroup C disease in persons over 
25 years dropped from 0.55 per 100,000 persons to 0.02 
per 100,000 persons; and the number of cases in infants 
under 3 months of age dropped from 13 in 1998 to one 
in 2009.88 These effects were seen despite a declining 
seroprevalence of protective antibodies among vaccination 
cohorts as early as 18 months after the last scheduled 
dose of vaccine, suggesting sustained protection due to 
herd immunity despite absence of protective antibodies 
in individuals.89 Additional suggestions of herd immunity 
come from Ontario, where a 16% reduction per year in 
serogroup C disease occurred among persons $20 years 
of age from 2000–2006 following introduction of an MCC 
vaccination program in adolescents and infants in 2001.90 
Herd immunity has not been demonstrated in the United 
States, where coverage with quadrivalent meningococcal 
vaccine among adolescents has increased slowly in the 
5 years since introduction.
Future directions
Meningococcal conjugate vaccination programs in the 
meningitis belt are just beginning and have potential to 
eliminate epidemic serogroup A meningococcal disease 
as a public health concern in the region. In 2010, Burkina 
Faso, Mali, and Niger implemented large-scale vaccina-
tion campaigns country or district wide, vaccinating all 
persons ages 1–29 years.63 Programs of mass vaccination 
campaigns followed by routine infant or early childhood 
vaccination were modeled on the successful experience 
in the UK. As the vaccine is implemented, case-based, 
laboratory-confirmed surveillance is crucial to evaluating 
the early long-term impact on both disease and the circulat-
ing strains. Special studies are also needed to understand 
impact on carriage and vaccine effectiveness.
To maximize impact at an acceptable cost is the   challenge 
for meningococcal vaccination programs in industrialized 
countries. The Advisory Committee on Immunization 
Practices in the US recently recommended adding a booster 
dose of MenACWY for all 16-year-olds, 5 years after their 
initial dose, because early data suggested clinically relevant 
waning immunity. In contrast,   reductions in serogroup C 
disease persist over 10 years after the catch-up campaigns 
in the UK. There is no evidence for strain replacement in 
England and Wales following implementation of a nation-
wide conjugate vaccine   program.91 Nonetheless, there is 
evidence of increased genetic diversity in strains causing 
invasive disease in the UK and ongoing surveillance is 
necessary.92 Countries continue to monitor for increases 
in disease caused by serogroups not in their current vac-
cination program, and meningococcal vaccination pro-
grams will surely adapt to changes in disease patterns in 
the future.
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